"Performance" YZYBIO's annual loss narrowed to RMB 84.732 millionAASTOCKS·Mar 29 at 09:52 PM024960.00%
Wuhan YZY Biopharma (SEHK:2496) Loss Deepens In 1H 2025 Challenging Improving Loss Trend NarrativeSimplywall·Mar 29 at 04:40 AM024960.00%
Hong Kong Stock Movement: YZYBIO-B fell by 12.28%, with clear capital flow and increased volatility attracting market attentionHK Stock Alerts·Mar 17 at 02:06 AM024960.00%
Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural EffusionTip Ranks·Feb 3 at 04:40 AM024960.00%
YZYBIO is selling industrial land in Wuhan for RMB 36.88 millionAASTOCKS·Jan 25 at 05:07 AM024960.00%
YZYBIO's biosimilar Y225 clinical trial application approvedAASTOCKS·Dec 28, 2025 at 04:39 AM024960.00%
YZYBIO-B: Mid-term data from the Phase II study of M701 for malignant pleural effusion will be announced at the 2025 ESMO conferenceZhitong·Oct 19, 2025 at 05:22 AM024960.00%
YZYBIO-B: Wang Tao elected as employee representative supervisorZhitong·Sep 18, 2025 at 03:53 AM024960.00%
YZYBIO-B released its interim results, with a net loss of 58.834 million yuan, narrowing by 25% year-on-yearZhitong·Aug 26, 2025 at 04:46 AM024960.00%
YZYBIO-B plans to implement the H-share full circulation planZhitong·May 12, 2025 at 07:17 AM024960.00%
